Niagen Bioscience (NAGE) Long-Term Deferred Tax (2016 - 2019)

Niagen Bioscience (NAGE) has 4 years of Long-Term Deferred Tax data on file, last reported at $30.5 million in Q4 2019.

• Long-Term Deferred Tax for Q4 2019 came in at $30.5 million, up 38.34% year-over-year; the trailing twelve-month figure through Dec 2019 was $30.5 million (up 38.34% YoY), and the FY2019 annual result was $30.5 million, up 38.34% from the prior year.
• Long-Term Deferred Tax advanced to $30.5 million in Q4 2019 per NAGE's latest filing, from $22.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $30.5 million in Q4 2019 and troughed at $413000.0 in Q1 2016.
• A 4-year average of $16.4 million and a median of $15.9 million in 2016 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2016 and 2017: Long-Term Deferred Tax jumped 3756.9% in 2016, then decreased 18.09% in 2017.
• A 4-year view of Long-Term Deferred Tax shows it stood at $15.9 million in 2016, then slipped by 18.09% to $13.0 million in 2017, then jumped by 69.14% to $22.1 million in 2018, then soared by 38.34% to $30.5 million in 2019.
• Business Quant data shows NAGE's Long-Term Deferred Tax at $30.5 million in Q4 2019, $22.1 million in Q4 2018, and $13.0 million in Q4 2017.